Professor, Radiation Oncology, Medical College of Wisconsin
Radiation Oncology
Dr. Colleen A. Lawton, MD
|
|
Give Review
Colleen Lawton is an expert in the field of Radiation Oncology. She went to Medical College of Wisconsin. Medical College of Wisconsin is ranked 54 in research and 62 in primary care medicine She over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Colleen A. Lawton is a published doctor and has 91 publications published. The lastest was: 'Prostatic carcinoma.' She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413.
- Assessment and management of interfractional variations in daily diagnostic-quality-CT guided prostate-bed irradiation after prostatectomy.
- SU-E-T-579: Dosimetric Benefits of Online Adaptive Replanning for Post-Operative Radiation Therapy of Prostate Bed.
- SU-E-J-11: Characterization of Interfractioanal Anatomical Variations in Post-Operative Radiation Therapy for Prostate Bed.
- Consolidating risk estimates for radiation-induced complications in individual patient: late rectal toxicity.
- Mitigation of Late Renal and Pulmonary Injury After Hematopoietic Stem Cell Transplantation.
- Long-Term Results of a Phase II Trial of Ultrasound-Guided Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prosta...
- To treat pelvic nodes or not? Greater testicular scatter does not explain the results of randomized trials.
- Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy.
- ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate.
- Results of the Association of Directors of Radiation Oncology Programs (ADROP) survey of radiation oncology residency program directors.
- Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.
- Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate ...
- Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy on...
- An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG ...
- Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma o...
- A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019.
- Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of ...
- Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
- Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
- Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on...
- Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate.
- Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy...
- Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Th...
- Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomize...
- Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radia...
- Pelvic lymph node irradiation for prostate cancer: who, why, and when?
- Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.
- Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
- Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Th...
- Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy...
- Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
- A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate:...
- Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate?
- Online adaptive replanning method for prostate radiotherapy.
- Influence of number of CAG repeats on local control in the RTOG 86-10 protocol.
- Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.
- Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.
- A comparison of daily megavoltage CT and ultrasound image guided radiation therapy for prostate cancer.
- Prostate cancer: are racial differences in clinical stage and survival explained by differences in symptoms?
- Technical modifications in hyperfractionated total body irradiation for T-lymphocyte deplete bone marrow transplant.
- Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer.
- p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
- Older Age Predicts Decreased Metastasis and Prostate Cancer-Specific Death for Men Treated with Radiation Therapy: Meta-Analysis of Radiation Therapy Oncology Group Tr...
- Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610.
- Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology...
- Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the...
- Validation of an online replanning technique for prostate adaptive radiotherapy.
- Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose.
- An on-line replanning scheme for interfractional variations.
- Prostatic carcinoma.
- Extended-field radiation therapy for prostatic carcinoma with para-aortic lymph node metastasis.
- Hypofractionation for prostate cancer.
- Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation.
- Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
- Development of an online adaptive solution to account for inter- and intra-fractional variations.
- Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Grou...
- Effect of nephrotoxic drugs on the development of radiation nephropathy after bone marrow transplantation.
- Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer.
- Pulmonary function changes in long-term survivors of bone marrow transplantation.
- Loss of renal function following bone marrow transplantation: an analysis of angiotensin converting enzyme D/I polymorphism and other clinical risk factors.
- Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors.
- Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients.
- Node-positive prostatic carcinoma.
- Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors.
- Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic ...
- Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia.
- Late renal dysfunction in adult survivors of bone marrow transplantation.
- Clinical course of late-onset bone marrow transplant nephropathy.
- Bone marrow transplant nephropathy: radiation nephritis revisited.
- T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin''s lymphoma: clinical and molecular follow-up.
- Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults.
- Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings.
- Coronary flow reserve after ischemia and reperfusion of the isolated heart. Divergent results with crystalloid versus blood perfusion.
- Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow tr...
- RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.
- Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer.
- Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol.
- Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
- Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
- Combined online and offline adaptive radiation therapy: A dosimetric feasibility study.
- Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.
- RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer.
- The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted surviv...
- Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate...
- Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy.
- Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.
- Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).
- Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy...
- Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiat...
Schools
Medical College of Wisconsin
Milwaukee Co Hospital
Med College Wisc Affil Hospital
Conditions Treated
- Genitourinary Cancers
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Medical College of Wisconsin Affiliated Hospitals -
Medical College of Wisconsin
Hospital
-
Children's Hospital of Wisconsin -
Froedtert Memorial Lutheran Hospital
Drug Facts
| NPI NUMBER | 1669423596 | |
| NPPES Provider LastName | LAWTON | |
| NPPES Provider FirstName | COLLEEN | |
| NPPES Provider ZIPCode | 532263522 | |
| NPPES Provider State | WI | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 57.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1669423596 |
| Last Name Of The Provider | LAWTON |
| First Name Of The Provider | COLLEEN |
| View All |
Similar Doctors
|
|
Dr. Beth Erickson, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Joseph Bovi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Tracy Kelly, MD |
|
Dr. Julia White, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John D. Naida, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam Currey, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Dian Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellen L. Ziaja, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Selim Y. Firat, MD
This Doctor is OpenDoctor Recommended.
|